go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd
Stonemason's Way, Rathfarnham, Dublin 16,
Telephone: +353 1 495 5000
Fax: +353 1 495 5105
Medical Information Direct Line: +353 1 800 244 255
Medical Information Facsimile: +353 1 495 5242


Summary of Product Characteristics last updated on medicines.ie: 06/05/2010
SPC Betnovate RD Ointment

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipient(s)
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Betnovate RD (Ready Diluted) 0.025% w/w Ointment


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Betamethasone 0.025% w/w (as Betamethasone valerate).

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Ointment.

A smooth, off-white soft-paraffin based ointment


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Betamethasone is indicated in the topical management of corticosteroid responsive dermatoses such as eczema in children and adults, including atopic and discoid eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, including lichen simplex, lichen planus, seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalized erythroderma.

Betamethasone Valerate is a potent glucocorticoid absorbed in part after topical use. Betnovate RD preparations are indicated for maintenance treatment when control has been achieved with Betnovate.


Go to top of the page
4.2 Posology and method of administration

Application to the affected area usually one to three times daily, or as directed by the physician.

When improvement occurs frequency of use should be gradually reduced.

Betnovate RD ointment is especially appropriate for dry, lichenified or scaly lesions, but this is not invariably so.


Go to top of the page
4.3 Contraindications

Rosacea, acne vulgaris, primary cutaneous viral infections, perianal and genital pruritus and peri-oral dermatitis.

Use in the presence of untreated infections of bacterial, viral, tuberculous or fungal origin.

Use in primary cutaneous viral infections (e.g. herpes simplex, chickenpox). Hypersensitivity to any ingredients of the preparations.

Dermatoses in children under one year of age, including dermatitis and napkin eruptions. Widespread plaque psoriasis except single lesions.


Go to top of the page
4.4 Special warnings and precautions for use

Prolonged use of uninterrupted occlusion (including napkins) or use with extensive occlusive dressing may suppress adrenocortical function. Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur even without occlusion. Continuous treatment for longer than three weeks should be avoided in patients under the age of three years because of the possibility of adrenocortical suppression or of growth suppression, systemic absorption and hypercorticism.

The face, more than other areas of the body, may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids. This must be borne in mind when treating such conditions as psoriasis, discoid lupus erythematosus and severe eczema.

If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as glaucoma might result.

Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses on cessation of use, development of tolerances, risk of generalized pustular psoriasis, excessive systemic absorption and development of local or systemic toxicity due to impaired barrier function of the skin. If used in psoriasis careful patient supervision is important.

Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and systemic administration of antimicrobial agents. Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings, and so the skin should be cleansed before a fresh dressing is applied.

There have been a few reports in the literature of the development of cataracts in patients who have been using corticosteroids for prolonged periods of time. Although it is not possible to rule out systemic corticosteroids as a known factor, prescribers should be aware of the possible role of corticosteroids in cataract development.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Animal studies with corticosteroids have shown teratogenic effects. To date similar effects have not been shown to occur in man. This product should not be used during pregnancy or lactation unless considered essential by the physician.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (GREATER-THAN OR EQUAL TO (8805)1/10), common (GREATER-THAN OR EQUAL TO (8805)1/100 and <1/10), uncommon (GREATER-THAN OR EQUAL TO (8805)1/1000 and <1/100), rare (GREATER-THAN OR EQUAL TO (8805)1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Very common, common and uncommon events were generally determined from clinical trial data. The background rates in placebo and comparator groups were not taken into account when assigning frequency categories to adverse events derived from clinical trial data, since these rates were generally comparable to those in the active treatment group. Rare and very rare events were generally determined from spontaneous data.

Immune system disorders

Very rare:*Hypersensitivity.

If signs of *hypersensitivity appear, application should stop immediately.

Endocrine disorders

Very rare:*Features of hypercortisolism.

*As with other corticosteroids, prolonged use of large amounts or treatment of extensive areas, can result in sufficient systemic absorption to produce the *features of hypercortisolism. This effect is more likely to occur in infants and children, and if occlusive dressings are used. In infants, the napkin may act as an occlusive dressing.

Vascular disorders

Very rare:*Dilatation of the superficial blood vessels.

*Prolonged and intensive treatment with highly active corticosteroid preparations may cause *dilatation of the superficial blood vessels, particularly when occlusive dressings are used or when skin folds are involved.

Skin and subcutaneous tissue disorders

Common:*Local skin burning and *pruritus.
Very rare:*Thinning, *striae, *pigmentation changes, *hypertrichosis, allergic contact dermatitis, pustular psoriasis, *exacerbation of symptoms.

*Prolonged and intensive treatment with highly active corticosteroid preparations may cause *local atrophic changes in the skin such as *thinning, and *striae, particularly when occlusive dressings are used or when skin folds are involved.

In very rare instances, treatment of psoriasis with corticosteroid (or its withdrawal) is thought to have provoked the pustular form of the disease.


Go to top of the page
4.9 Overdose

Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse, the features of hypercorticisolism may appear and in this situation topical steroids should be discontinued gradually under medical supervision because of the risk of adrenal insufficiency.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Betamethasone valerate is a corticosteroid with topical anti-inflammatory activity.


Go to top of the page
5.2 Pharmacokinetic properties

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings on the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systematically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolised primarily by the liver and are then excreted by the kidneys.


Go to top of the page
5.3 Preclinical safety data

No additional data.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

White Soft Paraffin,

Liquid Paraffin.


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25oC. Store in the original package in order to protect from light.


Go to top of the page
6.5 Nature and contents of container

Betnovate RD ointment is supplied in 100g collapsible aluminium tubes.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

GlaxoSmithKline (Ireland) Limited,

Stonemasons Way,

Rathfarnham,

Dublin 16


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 1077/1/5


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

24th August 1984 / 24th August 2009


Go to top of the page
10. DATE OF REVISION OF THE TEXT

March 2010



Link to this document from your website:
http://www.medicines.ie/medicine/2206/SPC/Betnovate+RD+Ointment/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Betamethasone Valerate

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo